Last updated: September 6, 2026
The aspirin, butalbital, caffeine, and codeine phosphate combination is a mature, genericized prescription headache medicine historically marketed as Fiorinal with Codeine. Its U.S. commercial position is defined by low barriers to entry, fragmented generic supply, Schedule III opioid controls, and declining clinical preference for butalbital- and opioid-containing headache products. No meaningful composition-of-matter or formulation exclusivity remains. Product-specific revenue is not separately disclosed by major manufacturers, so the financial outlook must be assessed through prescription demand, generic pricing, controlled-substance exposure, and broader headache-market substitution.
What drug contains aspirin, butalbital, caffeine, and codeine phosphate?
The combination is commonly identified as Fiorinal with Codeine and its generic equivalents.
| Component |
Typical capsule strength |
Commercial function |
| Aspirin |
325 mg |
Analgesic and anti-inflammatory |
| Butalbital |
50 mg |
Barbiturate muscle relaxant and sedative |
| Caffeine |
40 mg |
Analgesic adjuvant |
| Codeine phosphate |
30 mg |
Opioid analgesic |
The product is indicated for relief of symptom complexes involving tension or muscle-contraction headache when non-opioid alternatives are inadequate. It is an immediate-release oral capsule or tablet product, not a long-acting delivery system or biologic.
The product has several safety constraints: aspirin-related gastrointestinal bleeding, butalbital dependence and withdrawal, codeine-related respiratory depression, medication-overuse headache, and additive central nervous system depression. FDA labeling also identifies risks from concomitant use with alcohol, benzodiazepines, and other central nervous system depressants (FDA, 2023a).
What is the FDA regulatory status of Fiorinal with Codeine?
Fiorinal with Codeine is an FDA-approved prescription drug and contains a federally controlled opioid-barbiturate combination. Codeine-containing formulations of this type are generally classified as Schedule III under the federal Controlled Substances Act because they contain limited quantities of codeine in combination with non-narcotic ingredients. State scheduling and dispensing requirements can be more restrictive.
The reference product is associated with FDA NDA 018651. Generic versions are approved through abbreviated new drug applications, allowing applicants to demonstrate bioequivalence rather than repeat the full clinical development program.
FDA regulatory milestones
| Regulatory issue |
Status |
| Approval pathway |
Original NDA followed by ANDA generic approvals |
| Dosage form |
Immediate-release oral capsule or tablet |
| Prescription status |
Prescription-only |
| Controlled-substance status |
Schedule III in the U.S. federal system |
| FDA therapeutic category |
Analgesic combination for headache symptoms |
| Pediatric use |
Restricted by opioid safety rules and labeling limitations |
| Exclusivity |
No current new-drug exclusivity expected for this legacy product |
| REMS or product-specific exclusivity |
No commercial exclusivity barrier comparable to a modern branded opioid product |
FDA has tightened labeling for codeine and other opioid products, especially in pediatric populations and breastfeeding. The combination’s age, controlled-substance status, and established safety risks reduce its attractiveness for new clinical development.
What patents protect aspirin, butalbital, caffeine, and codeine phosphate?
No active composition-of-matter patent protects the four-ingredient combination. The product was approved decades ago, and the underlying active ingredients are long-established generic substances.
Orange Book status
The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity associated with approved drug products. For this legacy combination, the commercial market is not protected by a current patent estate comparable to newer branded pharmaceuticals. The relevant commercial barriers are manufacturing compliance, controlled-substance distribution controls, state prescribing rules, and supplier qualification.
| Patent category |
Current commercial relevance |
| Active ingredient patent |
None |
| Combination patent |
No meaningful remaining exclusivity identified |
| Original formulation patent |
Expired or commercially irrelevant |
| Method-of-use patent |
No material barrier to generic dispensing |
| Device or delivery patent |
Not applicable |
| Pediatric exclusivity |
Not a current market barrier |
| New chemical entity exclusivity |
Expired decades ago |
What formulations are protected?
The commercial formulations are conventional immediate-release capsules and tablets. They do not depend on a proprietary extended-release matrix, transdermal system, injectable presentation, or device. That limits opportunities for defensive formulation patents.
A manufacturer could seek patents on manufacturing processes, particle size, excipients, packaging, or stability characteristics. Those patents would not ordinarily block generic approval of the basic product unless they covered a necessary production method and survived validity and infringement challenges. In practice, the formulation is sufficiently conventional that manufacturing know-how is a more relevant operational asset than enforceable exclusivity.
When does aspirin, butalbital, caffeine, and codeine lose exclusivity?
The combination lost meaningful market exclusivity many years ago. The relevant patent and regulatory exclusivity periods expired before the current generic market was established.
| Exclusivity element |
Timing |
| Original active-ingredient exclusivity |
Expired |
| Original combination exclusivity |
Expired |
| FDA new-drug exclusivity |
Expired |
| Generic entry |
Established |
| Current patent cliff |
None |
| Near-term exclusivity event |
None identified |
This is not a product approaching a patent cliff. It is a post-cliff generic market in which price, supply reliability, wholesaler access, and regulatory compliance determine commercial performance.
How many patents cover this drug?
No material set of unexpired Orange Book patents is expected to constrain generic entry for the standard four-ingredient product. The number of patents that may exist in broader patent databases is not the same as the number of patents capable of blocking approval or sale.
Potential peripheral patents can include:
- Manufacturing processes for butalbital or codeine-containing granules.
- Capsule-shell or packaging technologies.
- Stability and moisture-control methods.
- Hospital or pharmacy workflow systems.
- Alternative dosage forms.
- Combination products that omit one or more active ingredients.
These patents do not create a strong estate around the standard aspirin, butalbital, caffeine, and codeine phosphate capsule.
Which companies manufacture or challenge the product?
The market is supplied through generic drug manufacturers and contract manufacturers rather than a single dominant branded company. U.S. availability can vary by product listing, wholesaler inventory, controlled-substance quotas, and manufacturing decisions.
Potential suppliers in this therapeutic category have included large generic manufacturers such as Teva, Amneal, Hikma, and other ANDA holders, depending on the specific strength, dosage form, and marketing status. Product ownership and labeler status can change over time, and a company listed in FDA databases is not necessarily the current commercial supplier in every channel.
Paragraph IV challenge risk
Paragraph IV litigation is a low-value issue for this product because the relevant branded exclusivity has expired. ANDA applicants do not need to challenge a commercially meaningful patent estate to enter the market. Any historical Paragraph IV activity would have been associated with old listings and would not materially alter current generic competition.
The principal entry risks are practical rather than patent-based:
- Controlled-substance manufacturing and distribution requirements.
- FDA inspection findings.
- Shortages of codeine, butalbital, or qualified active pharmaceutical ingredients.
- State-level prescribing restrictions.
- Wholesaler refusal to handle low-volume Schedule III products.
- Product discontinuation caused by weak margins.
What patent litigation affects Fiorinal with Codeine?
No major current patent litigation is known to define the market for the standard combination. Patent disputes are less likely than regulatory or commercial disputes because the product has no meaningful remaining exclusivity.
The more relevant legal exposure involves:
- Opioid prescribing and dispensing controls.
- Controlled-substance diversion investigations.
- Product-liability claims involving dependence, overdose, or medication-overuse headache.
- False-marketing or promotional claims.
- Manufacturing quality and data-integrity enforcement.
- State opioid settlement and distributor compliance obligations.
The litigation profile therefore differs from newer branded drugs. A generic manufacturer is more likely to face operational and product-liability exposure than an Orange Book patent injunction.
How strong is the patent estate for this combination?
The patent estate is weak from an exclusivity perspective.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Very weak or nonexistent |
| Formulation protection |
Weak |
| Method-of-use protection |
Weak |
| Manufacturing protection |
Potentially narrow and nonblocking |
| Orange Book leverage |
Low |
| Generic litigation leverage |
Low |
| Ability to support premium pricing |
Minimal |
| Lifecycle-management potential |
Limited |
A company attempting to create value around this molecule combination would need to change the product’s clinical or commercial profile. Possibilities could include an abuse-deterrent formulation, a non-opioid replacement, a lower-risk headache regimen, or a proprietary delivery system. Each would require new clinical, regulatory, and reimbursement investment and would compete against increasingly preferred non-opioid therapies.
What is the financial trajectory of the product?
The financial trajectory is mature to declining in unit demand and heavily exposed to generic price erosion. The product is unlikely to generate material standalone revenue for a diversified pharmaceutical company.
Revenue drivers
Demand is supported by:
- Existing prescribers familiar with the product.
- Patients who report benefit from combination therapy.
- Low generic acquisition cost.
- Continued use in selected tension-headache and refractory headache cases.
- Limited development costs for existing ANDA holders.
Demand is constrained by:
- Clinical concerns over butalbital dependence.
- Opioid stewardship programs.
- Medication-overuse headache.
- Availability of triptans, gepants, ditans, NSAIDs, acetaminophen, and preventive therapies.
- Payer preference for non-opioid products.
- Controlled-substance inventory and prescribing friction.
- Low reimbursement and generic price competition.
The product’s revenue curve likely follows a mature-generic pattern: an initial branded revenue period, rapid erosion after generic entry, long-term low-price maintenance, and eventual contraction as manufacturers discontinue low-margin presentations.
Financial exposure by stakeholder
| Stakeholder |
Financial effect |
| Branded innovator |
Limited current revenue opportunity |
| Generic manufacturer |
Low unit margin with possible niche volume |
| Contract manufacturer |
Volume depends on quota and supply continuity |
| Wholesaler |
Controlled-substance compliance raises handling costs |
| Payer |
Low ingredient cost but potential downstream utilization costs |
| Health system |
Limited acquisition expense; monitoring burden remains |
| Investors |
No clear standalone growth thesis without reformulation |
Public filings generally do not report revenue for this product separately. Sales are usually aggregated into broader generic portfolios, making product-specific revenue, gross margin, and market share unavailable from issuer disclosures.
How does this drug compare with competing headache medicines?
The combination competes against both acute and preventive therapies.
| Therapy class |
Competitive position versus the combination |
| NSAIDs |
Lower regulatory burden and generally preferred for many acute headaches |
| Acetaminophen |
Lower dependence risk, though efficacy varies |
| Triptans |
Preferred for many migraine attacks |
| Gepants |
Higher-cost but non-opioid migraine option |
| Ditans |
Non-vasoconstrictive acute migraine alternative |
| CGRP antibodies |
Preventive therapy, not a direct acute substitute |
| Butalbital without codeine |
Still exposed to dependence and medication-overuse concerns |
| Opioid combinations |
Similar safety and stewardship disadvantages |
The combination retains a niche where patients and prescribers seek a sedating analgesic with caffeine augmentation. Its clinical position is weaker in guidelines and formularies that prioritize migraine-specific, non-opioid, or preventive therapies.
What generic entry risks exist?
Generic entry itself is not the primary risk because generic products already compete in the market. The central risks are supply instability and demand erosion.
Generic launch scenarios
| Scenario |
Market effect |
| Additional ANDA entrants |
Further price pressure and lower margins |
| One or more manufacturers exit |
Temporary supply tightening and price recovery |
| FDA quality action |
Shortage risk and substitution to other products |
| Increased opioid controls |
Lower prescribing and slower dispensing |
| Reformulated competitor launch |
Potential migration away from the legacy product |
| Codeine or butalbital API disruption |
Higher costs and intermittent availability |
A new generic entrant would likely capture share through wholesaler contracting, pharmacy availability, and reliable supply rather than patent differentiation. Price competition can be severe because the product has limited clinical differentiation and low switching costs for prescribers and pharmacies.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more important than patent barriers. A compliant supplier must manage:
- Controlled-substance quotas.
- Security and recordkeeping requirements.
- Separate handling of codeine and butalbital.
- FDA current good manufacturing practice compliance.
- Validated blending and content-uniformity processes.
- Stability testing for aspirin degradation and moisture sensitivity.
- Qualified API suppliers.
- Serialization, packaging, and traceability requirements.
- State and federal distribution controls.
Aspirin introduces formulation and stability considerations because moisture can promote degradation. Butalbital and codeine require controlled-substance controls. These obligations can make the product unattractive to smaller manufacturers even when the legal entry barrier is low.
What licensing deals affect the product?
No major current licensing transaction is associated with the legacy combination’s core commercial rights. Generic supply arrangements are more likely to involve contract manufacturing, private-label distribution, or wholesaler agreements than high-value intellectual-property licenses.
A licensing opportunity would be more plausible for a redesigned product with:
- Abuse-deterrent technology.
- A non-opioid replacement.
- A differentiated formulation.
- New clinical data supporting a defined patient population.
- A proprietary combination that addresses medication-overuse risk.
The existing four-ingredient formulation has limited licensing value because it is easily substitutable and lacks enforceable exclusivity.
Key Takeaways
- Aspirin, butalbital, caffeine, and codeine phosphate is a legacy prescription combination associated with Fiorinal with Codeine.
- The product is FDA-approved, prescription-only, and generally treated as a Schedule III controlled substance in the U.S.
- No meaningful current patent or regulatory exclusivity protects the standard formulation.
- Generic competition is established, and Paragraph IV litigation is not a material current market issue.
- Product-specific revenue is not separately disclosed and is likely small relative to diversified manufacturers’ total sales.
- Demand faces long-term pressure from opioid stewardship, butalbital dependence concerns, medication-overuse headache, and migraine-specific alternatives.
- Supply reliability, controlled-substance quotas, FDA compliance, and wholesaler access are more important than patent rights.
- The commercial outlook is mature to declining, with limited upside unless a manufacturer develops a differentiated reformulation.
FAQs
Is Fiorinal with Codeine still available in the United States?
Generic aspirin, butalbital, caffeine, and codeine phosphate products may remain available, but availability varies by manufacturer, pharmacy inventory, controlled-substance quotas, and market withdrawals.
Is aspirin, butalbital, caffeine, and codeine phosphate a generic drug?
Yes. The combination is available through generic products approved under ANDAs, although individual manufacturers may market or discontinue specific strengths and dosage forms.
Can a generic manufacturer obtain exclusivity for this drug today?
A new applicant generally cannot obtain meaningful product exclusivity for the conventional formulation because the active ingredients and original product have long histories. Exclusivity could arise only from a qualifying new formulation, indication, or regulatory designation.
Does the product have biosimilar competition?
No. This is a chemically synthesized small-molecule combination, not a biologic. The relevant competitors are generic drugs and alternative headache therapies, not biosimilars.
What would increase the product’s commercial value?
Commercial value would require differentiation, such as an abuse-deterrent formulation, a validated lower-risk dosing strategy, a proprietary delivery system, or clinical evidence supporting a patient group underserved by non-opioid headache treatments.
References
-
U.S. Food and Drug Administration. (2023a). Fiorinal with Codeine prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2018). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. FDA.
-
U.S. Drug Enforcement Administration. (2023). Drug scheduling. U.S. Department of Justice.
-
American Headache Society. (2015). The American Headache Society evidence assessment of migraine pharmacotherapies. Headache, 55(1), 3-20.
